Trial Profile
A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Solid Tumor Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Jul 2022
Price :
$35
*
At a glance
- Drugs Dalpiciclib (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 20 Jun 2020 Status changed from recruiting to completed.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 11 Apr 2016 Status changed from not yet recruiting to recruiting.